Last updated: September 8, 2026
Ensifentrine is a first-in-class inhaled phosphodiesterase 3 and 4 inhibitor marketed by Verona Pharma as Ohtuvayre. The FDA approved it on June 26, 2024, for the maintenance treatment of chronic obstructive pulmonary disease, or COPD, in adults. It is the first nebulized, nonsteroidal maintenance therapy approved for COPD and entered a market dominated by inhaled long-acting bronchodilators, inhaled corticosteroid combinations and roflumilast tablets.
Ohtuvayre's commercial opportunity is substantial because COPD affects more than 16 million diagnosed Americans, while many additional patients remain undiagnosed. Verona reported initial U.S. net product revenue of approximately $14 million in the fourth quarter of 2024, its first commercial quarter. The principal value drivers are prescription growth, payer coverage, conversion of patients who cannot adequately use inhalers, and expansion into chronic bronchitis and other respiratory indications.
The central risks are launch execution, reimbursement friction, competition from established inhalers, the cost of twice-daily nebulizer treatment, and the absence of a long-acting bronchodilator indication on the initial label.
What is ensifentrine and how does Ohtuvayre work?
Ensifentrine is an inhaled small-molecule inhibitor of PDE3 and PDE4. PDE3 inhibition provides bronchodilation, while PDE4 inhibition provides anti-inflammatory activity. The drug is administered twice daily by nebulization.
Ohtuvayre's initial FDA indication is:
- Maintenance treatment of COPD in adults
- Delivered through a standard jet nebulizer
- Not indicated for relief of acute bronchospasm
- Not a rescue medication
- Not approved as an asthma treatment
The dual mechanism differentiates ensifentrine from:
| Therapy class |
Examples |
Main activity |
Key limitation relative to ensifentrine |
| Long-acting muscarinic antagonists |
Tiotropium, glycopyrronium |
Bronchodilation |
Limited direct anti-inflammatory activity |
| Long-acting beta agonists |
Salmeterol, formoterol, indacaterol |
Bronchodilation |
Limited direct anti-inflammatory activity |
| Inhaled corticosteroids |
Budesonide, fluticasone |
Anti-inflammatory |
Pneumonia and steroid-related risks in selected patients |
| PDE4 inhibitor |
Roflumilast |
Anti-inflammatory |
Oral dosing, gastrointestinal and weight-loss adverse effects |
| PDE3/PDE4 inhibitor |
Ensifentrine |
Bronchodilation and anti-inflammatory activity |
Twice-daily nebulizer administration |
Clinical trials showed improvements in lung function and reductions in moderate and severe COPD exacerbations relative to placebo. Verona's pivotal ENHANCE studies formed the principal evidence base for approval (Verona Pharma, 2023; U.S. Food and Drug Administration, 2024).
What is the FDA regulatory status of ensifentrine?
The FDA approved Ohtuvayre on June 26, 2024, through the standard New Drug Application pathway. The approval was based on the ENHANCE-1 and ENHANCE-2 Phase 3 trials, which enrolled patients with moderate to severe COPD.
The FDA label supports chronic maintenance use. It does not authorize treatment of acute exacerbations. Common adverse reactions include back pain, hypertension, diarrhea and insomnia. Psychiatric and weight-related warnings associated with oral PDE4 inhibition are commercially relevant because prescribers may compare ensifentrine with roflumilast, even though the route of administration differs.
The initial U.S. approval does not include:
- Asthma
- Cystic fibrosis
- Non-cystic-fibrosis bronchiectasis
- Acute COPD exacerbation treatment
- A metered-dose or dry-powder inhaler formulation
Verona is developing additional presentations and indications, but those programs do not contribute to current approved-product revenue until regulatory approval and commercial launch.
When does ensifentrine lose exclusivity?
Ohtuvayre benefits from both regulatory exclusivity and patent protection.
The five-year New Chemical Entity exclusivity period is expected to block submission of an abbreviated new drug application until June 2029, subject to statutory exceptions. FDA approval of a competing generic could occur later because ANDA review, patent litigation and potential pediatric extensions affect the practical timeline.
The relevant exclusivity framework is:
| Protection |
Expected timing |
Commercial effect |
| FDA approval |
June 26, 2024 |
U.S. commercial launch permitted |
| NCE exclusivity |
Through approximately June 2029 |
Blocks ordinary ANDA submission during the protected period |
| Patent protection |
Extends beyond NCE exclusivity |
May delay FDA approval or commercial launch of generics |
| Pediatric exclusivity |
Not assumed in base case |
Could add six months if granted |
| Formulation or device patents |
Potentially later expiry than composition claims |
Could restrict specific delivery systems or presentations |
The FDA Orange Book is the controlling source for listed Ohtuvayre patents and expiration dates. The patent estate is expected to include protection for ensifentrine compounds, pharmaceutical compositions, inhaled formulations and methods of treating respiratory disease. The commercial strength of the estate will depend on whether generic applicants can design around formulation or device claims while preserving the clinical and pharmacokinetic profile needed for approval (U.S. Food and Drug Administration, 2025).
What patents protect ensifentrine?
The strongest patent value is likely concentrated in four claim categories:
Active pharmaceutical ingredient claims
These claims cover ensifentrine and related chemical structures. Composition-of-matter claims generally provide the broadest protection because a generic applicant cannot avoid them merely by changing excipients or device components.
Inhaled formulation claims
Formulation patents can cover:
- Concentration of ensifentrine in the nebulized solution
- Buffer systems
- pH and osmolality
- Stability characteristics
- Particle or droplet delivery parameters
- Unit-dose packaging
- Preservative systems
A generic company may face additional barriers if the approved product's formulation is difficult to replicate without infringing claims or triggering a separate clinical and regulatory burden.
Method-of-use claims
Potential method claims can cover treatment of COPD, reduction of exacerbations, improvement in lung function and use in defined patient subgroups. Method-of-use patents are vulnerable to induced-infringement and skinny-label strategies, but they can still complicate generic commercialization.
Device and delivery claims
Ohtuvayre's nebulized route creates a potential device and combination-product layer. Protection may cover the interaction between the drug solution and the delivery system, although device claims may not prevent all alternative nebulizer approaches.
What is the Orange Book status of Ohtuvayre?
Ohtuvayre is an FDA-approved prescription drug subject to Orange Book listing. The Orange Book identifies patents and regulatory exclusivities that an ANDA applicant must address.
A future generic applicant could submit:
- Paragraph I certification if no patent is listed
- Paragraph II certification if the patent has expired
- Paragraph III certification accepting delayed approval until patent expiry
- Paragraph IV certification asserting that the patent is invalid, unenforceable or not infringed
The first commercially meaningful generic threat would most likely arise through a Paragraph IV filing after the NCE exclusivity barrier no longer prevents ANDA submission. A Paragraph IV notice could trigger patent litigation within 45 days and an automatic 30-month stay of FDA approval, subject to statutory limitations and court outcomes (U.S. Food and Drug Administration, 2025).
Which companies are challenging ensifentrine?
No major public Paragraph IV challenge was identified in the initial post-approval period through the end of 2024. That timing is expected. Ohtuvayre was newly approved, and the five-year NCE exclusivity period limits the attractiveness of an immediate ANDA filing.
Likely future challengers include:
- Large generic manufacturers with respiratory-device capabilities
- Companies selling nebulized COPD products
- Contract development and manufacturing organizations with sterile inhalation capacity
- Specialty generic companies targeting complex drug-device products
The most credible challenge may come from a company able to produce a therapeutically equivalent nebulized solution rather than from a conventional tablet-focused generic manufacturer.
How strong is the ensifentrine patent estate?
The patent estate is commercially meaningful but not automatically impenetrable.
Strengths include:
- A recently approved active ingredient with five years of NCE exclusivity.
- A differentiated inhaled formulation that may support separate formulation claims.
- A complex nebulized delivery route that raises manufacturing and equivalence issues.
- Clinical-use claims connected to COPD maintenance treatment.
- The ability to extend protection through additional presentations or indications if new patents are granted.
Weaknesses include:
- The possibility of a formulation design-around.
- Potentially narrower enforceability of method-of-use claims.
- The ability of a generic applicant to target an alternative nebulizer or presentation.
- The absence of an inhaler presentation in the initial approved product, which may limit device-related exclusivity.
- The potential for patent litigation before generic approval rather than an absolute commercial prohibition.
Patent value is therefore likely to be strongest through the early 2030s if core composition and formulation claims survive challenge. The practical generic-entry date will depend on Orange Book listings, patent term adjustments, litigation settlements and the outcome of any Paragraph IV case.
What is the commercial market for Ohtuvayre?
The U.S. COPD market is large, established and highly genericized. The main products include long-acting bronchodilators, fixed-dose combinations and inhaled corticosteroid combinations. Ohtuvayre does not need to replace all existing maintenance therapies to reach blockbuster sales. It can target several commercially attractive segments:
- Patients with persistent symptoms despite bronchodilator therapy
- Patients with recurrent exacerbations
- Patients who cannot use handheld inhalers effectively
- Patients with poor adherence to complex inhaler regimens
- Patients for whom chronic inhaled corticosteroid exposure is undesirable
- Patients who cannot tolerate oral roflumilast
The nebulizer route is both a market opportunity and a constraint. It may improve access for patients with poor inspiratory flow, impaired coordination or advanced disease. It also adds treatment time, equipment requirements and caregiver burden.
How does ensifentrine compare with roflumilast?
Roflumilast is the most direct pharmacologic comparator because both drugs inhibit PDE4-related inflammatory pathways. The commercial differences are material.
| Attribute |
Ensifentrine |
Roflumilast |
| Route |
Inhaled nebulized solution |
Oral tablet |
| Mechanism |
PDE3 and PDE4 inhibition |
Selective PDE4 inhibition |
| Primary use |
COPD maintenance |
COPD exacerbation-risk reduction in selected patients |
| Bronchodilation |
Direct PDE3 component |
Limited direct bronchodilation |
| Common tolerability concerns |
Diarrhea, back pain, hypertension, insomnia |
Diarrhea, nausea, weight loss, psychiatric effects |
| Adherence burden |
Twice-daily nebulization |
Once-daily oral dosing |
| Commercial positioning |
Local pulmonary delivery and dual activity |
Oral anti-inflammatory add-on therapy |
Ohtuvayre's opportunity is greatest where inhaled delivery and bronchodilation matter. Roflumilast retains an adherence advantage because it is taken once daily without a nebulizer.
What was the initial financial performance of Ohtuvayre?
Verona began commercial sales in the second half of 2024. The company reported approximately $14 million in Ohtuvayre net product revenue for the fourth quarter of 2024, representing the first full commercial quarter after launch. The figure established initial market access but remained too early to determine the product's mature run rate (Verona Pharma, 2025).
The early financial trajectory depends on four operating indicators:
| Indicator |
Why it matters |
| New prescriptions |
Measures physician adoption |
| Refill rate |
Indicates persistence and real-world tolerability |
| Covered lives |
Determines access without prior authorization |
| Gross-to-net adjustment |
Measures rebates, discounts and patient assistance costs |
A launch that produces strong new prescriptions but weak refills would indicate tolerability, device or adherence problems. Strong refill performance would support a higher peak-sales valuation.
Verona's pre-commercial financial profile was typical of a development-stage biotechnology company: substantial research and development spending, limited product revenue and reliance on cash reserves and capital-market access. Commercial revenue reduces dependence on financing, but the company must continue funding manufacturing scale-up, post-approval studies, sales infrastructure and pipeline expansion.
What are the revenue scenarios for ensifentrine?
A practical U.S. revenue framework is:
| Scenario |
Commercial assumptions |
Approximate long-term U.S. revenue profile |
| Downside |
Slow payer adoption, limited refills, strong inhaler competition |
Below $300 million annually |
| Base case |
Steady pulmonologist adoption, growing primary-care use, durable refills |
$500 million to $1 billion annually |
| Upside |
Broad payer access, high use in difficult-to-treat COPD, successful new indications |
Above $1 billion annually |
These are scenario ranges rather than company guidance. Peak sales will depend on net price, treatment duration and the percentage of COPD patients receiving the product. International commercialization could increase value, but regulatory approvals, reimbursement systems and commercial partnerships will determine whether ex-U.S. markets produce material revenue.
What licensing deals affect ensifentrine?
Verona retains the central commercial and development rights to ensifentrine. The company's value is therefore more directly exposed to Ohtuvayre's operating performance than it would be under a large-partner model.
Potential strategic transactions could involve:
- Ex-U.S. commercialization rights
- Regional licensing
- Co-promotion with a respiratory company
- Device manufacturing or supply agreements
- Development partnerships for asthma, bronchiectasis or cystic fibrosis
A licensing deal could reduce Verona's commercial investment requirements and provide validation, but it would also transfer part of the economics to a partner. The absence of a major global partner leaves more upside with Verona and places greater execution responsibility on its commercial organization.
What generic entry risks exist for ensifentrine?
Generic entry is unlikely to be an immediate revenue threat. The nearer-term commercial risks are payer restrictions, physician adoption and competition from established inhaled therapies.
The longer-term generic risk profile includes:
- Paragraph IV challenges after NCE exclusivity
- Litigation over composition and formulation patents
- Alternative nebulizer designs
- A generic solution that relies on a different device
- Authorized generic or settlement arrangements
- Price erosion after the first approved equivalent
A generic nebulized product could face higher manufacturing costs than a conventional oral generic. Sterile liquid production, unit-dose packaging, stability testing and device compatibility may reduce the speed and depth of price erosion. The same factors, however, can raise the cost of Ohtuvayre's own supply chain.
What manufacturing and geographic barriers affect ensifentrine?
Ensifentrine requires pharmaceutical-grade production of a nebulized solution and reliable packaging for repeated administration. Manufacturing priorities include chemical purity, solution stability, container-closure integrity and consistent delivery performance.
The United States is the initial commercial market and the principal near-term revenue source. Geographic expansion requires:
- Country-specific regulatory approvals
- Local reimbursement decisions
- Distribution infrastructure
- Device and labeling compliance
- Commercial partners in markets where Verona lacks scale
The largest international opportunities are likely markets with high COPD prevalence, established nebulizer use and reimbursement for maintenance respiratory therapies. Europe may provide meaningful long-term value, but market access could be slower because of country-level pricing negotiations.
Key Takeaways
- Ohtuvayre is the first FDA-approved inhaled PDE3/PDE4 inhibitor for COPD maintenance.
- FDA approval occurred on June 26, 2024.
- Verona reported approximately $14 million in fourth-quarter 2024 net product revenue.
- The five-year NCE exclusivity period is expected to run until approximately June 2029.
- Patent protection may extend beyond NCE exclusivity through composition, formulation, method-of-use and delivery claims.
- The main commercial differentiation is dual bronchodilator and anti-inflammatory activity delivered by nebulizer.
- The primary adoption barriers are twice-daily administration, device burden and competition from established inhalers.
- A reasonable long-term revenue range is several hundred million dollars to more than $1 billion annually, depending on payer access and refill persistence.
- No major public Paragraph IV challenge was identified during the initial post-approval period through year-end 2024.
- The largest near-term risks are commercial execution and reimbursement, not immediate generic competition.
FAQs
Is ensifentrine a biologic or a small-molecule drug?
Ensifentrine is a small-molecule drug. It is not a biologic and therefore does not face biosimilar competition. Future competitors would generally use the generic drug pathway rather than the biosimilar pathway.
Is Ohtuvayre a rescue inhaler?
No. Ohtuvayre is a maintenance treatment for COPD and is not approved for rapid relief of acute bronchospasm or COPD exacerbations.
Can ensifentrine replace Trelegy or Anoro?
Ohtuvayre is not a direct one-for-one replacement for every fixed-dose inhaler. Physicians may use it as an add-on or alternative in selected patients, particularly those with persistent symptoms, exacerbation risk or difficulty using handheld inhalers.
Does ensifentrine have an asthma indication?
No. The initial FDA approval is limited to maintenance treatment of COPD. An asthma indication would require separate clinical evidence and regulatory approval.
Why is the nebulizer route commercially important?
Nebulization can help patients who have poor inspiratory flow, impaired hand-breath coordination or difficulty using dry-powder and metered-dose inhalers. The tradeoff is longer administration time and the need for equipment.
References
-
U.S. Food and Drug Administration. (2024). Ohtuvayre prescribing information: Ensifentrine inhalation suspension. FDA.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.
-
Verona Pharma plc. (2023). Phase 3 ENHANCE-1 and ENHANCE-2 clinical trial results for ensifentrine in COPD. Company clinical and regulatory disclosures.
-
Verona Pharma plc. (2025). Full-year 2024 financial results and commercial update. Company investor-relations disclosure.
